COVID-19 pandemic and exacerbation of ulcerative colitis

Table 1 Characteristics of the study participants

	Subjects (n = 289)	Controls (n = 256)	Probability
Age (yr)	45.0 ± 15.8	44.6 ± 15.6	0.6911
Sex (M/F)	147/141	125/131	0.6351
Height (cm)	163.6 ± 8.6	163.2 ± 8.4	0.6679
Weight (kg)	60.1 ± 11.3	59.9 ± 11.2	0.7465
Disease duration (yr)	11.6 ± 8.5	10.9 ± 8.2	0.3227
Smokers	69 (23.8%)	65 (25.3%)	0.7426
Disease extent
Total colitis	136 (47.0%)	129 (50.1%)	0.4373

No significant differences were seen between patients and patient controls for age, weight, height, disease duration, smoker rate, sex, or disease extent as total colitis rate.

Table 2 Pharmacotherapies used before presentation in patients and controls

Drug	Patients (n = 289)	Controls (n = 256)
5-ASA	165 (57.0%)	148 (57.8%)
AZA or
6-MP	35 (12.1%)	33 (12.8%)
IFX	36 (12.4%)	34 (13.2%)
ADA	26 (8.9%)	19 (7.4%)
GLM	9 (3.1%)	8 (3.1%)
TFN	2 (0.6%)	0 (0%)
TF	8 (2.7%)	6 (2.3%)
IR	5 (1.7%)	6 (2.3%)
PSL	1 (0.3%)	1 (0.3%)
CHM	1 (0.3%)	1 (0.3%)
ND	1 (0.3%)	0 (0%)

Medications used before presentation did not differ significantly between subjects and controls. ASA: Aminosalicylic acid; AZA: Azathioprine; MP: Mercapton; IFX: Infliximab; ADA: Adalimumab; GLM: Golimumab; TFN: Tofacitinib; TF: Topical formulation; IR: Intestinal regulator; PSL: Prednisolone; CHM: Chinese herbal medicine; ND: No drug.